Skewing dendritic cell differentiation towards a tolerogenic state for recovery of tolerance in rheumatoid arthritis.

摘要: To date, the available options to treat autoimmune diseases such as rheumatoid arthritis (RA) include traditional corticoids and biological drugs, which are not exempt of adverse effects. The development cellular therapies based on dendritic cells with tolerogenic functions (TolDCs) has opened a new possibility efficiently eradicate symptoms control immune response in field autoimmunity. TolDCs an attractive tool for antigen-specific immunotherapy restore self-tolerance RA other disorders. A promising strategy is inject autologous self-antigen-loaded TolDCs, able delete or reprogram autoreactive T cells. Different protocols generation stable human have been established therapeutic effect investigated multiple rodent models arthritis. Pilot studies humans confirmed that TolDC application safe, encouraging clinical trials using patients. Although abundance molecular regulators DC discovered last decade, no master regulator tolerogenicity identified yet. Further research required define biomarkers key might facilitate induction monitoring TolDCs.